Evidence map›Paper›PMID 26390291›Full record

ArticlePloS one2015

Altered Osteocyte-Specific Protein Expression in Bone after Childhood Solid Organ Transplantation.

Renata C Pereira, Helena Valta, Navdeep Tumber, Isidro B Salusky, Hannu Jalanko, Outi Mäkitie, Katherine Wesseling Perry

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in PloS one, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
2.3field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 24 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 3 countries.

Renata C PereiraDepartment of Pediatrics, David Geffen School of Medicine at UCLA, Los Angeles, United States of America.
Helena ValtaChildren's Hospital, Helsinki University Central Hospital, University of Helsinki, Helsinki, Finland.
Navdeep TumberDepartment of Pediatrics, David Geffen School of Medicine at UCLA, Los Angeles, United States of America.
Isidro B SaluskyDepartment of Pediatrics, David Geffen School of Medicine at UCLA, Los Angeles, United States of America.
Hannu JalankoChildren's Hospital, Helsinki University Central Hospital, University of Helsinki, Helsinki, Finland.
Outi MäkitieChildren's Hospital, Helsinki University Central Hospital, University of Helsinki, Helsinki, Finland; Folkhälsan Research Center, Helsinki, Finland; Department of Molecular Medicine and Surgery and Center for Molecular Medicine, Karolinska Institutet, Stockholm, Sweden.
Katherine Wesseling PerryDepartment of Pediatrics, David Geffen School of Medicine at UCLA, Los Angeles, United States of America.
University of California, Los Angeles · USUniversity of Helsinki · FI

Funding

FGF-23 Regulation in Chronic Kidney DiseaseK23DK080984 · NIDDK · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI WESSELING-PERRY, KATHERINE · 2009 to 2013
$872k
Osteoblast and Osteocyte Dysfunction in Chronic Kidney DiseaseR03DK098627 · NIDDK · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI WESSELING-PERRY, KATHERINE · 2014 to 2015
$154k
NIDDK NIH HHS K23 DK080984NIDDK NIH HHS K23DK080984NIDDK NIH HHS R03 DK098627NIDDK NIH HHS R03DK098627
6 · The paper itself

Abstract

backgroundBone fragility is common post solid organ transplantation but little is known about bone pathology on a tissue level. Abnormal osteocytic protein expression has been linked to compromised bone health in chronic kidney disease (CKD) and immunosuppressant medications may impact osteocyte function.

methodsTransiliac bone biopsies were obtained from 22 pediatric solid organ allograft recipients (average age 15.6 years) an average of 6.3 ± 1.2 years after transplantation and from 12 pediatric pre-dialysis CKD patients (average age 13.2 years). Histomorphometry and immunohistochemistry for FGF23, DMP1, sclerostin, and osteopontin were performed on all biopsies.

resultsFGF23 and sclerostin were increased in transplant recipients relative to non-transplant CKD, regardless of the type of allograft received and despite, in the case of liver and heart recipients, a higher GFR. Bone DMP1 expression was higher in liver or heart than in kidney recipients, concomitant with higher serum phosphate values. Osteopontin expression was higher in CKD than in transplant recipients (p<0.01). Bone FGF23 and sclerostin correlated directly (r = 0.38, p<0.05); bone FGF23 expression and osteoid thickness correlated inversely (r = - 0.46, p<0.01).

conclusionsSolid-organ transplantation is associated with increased FGF23 and sclerostin expression. The contribution of these findings to compromised bone health post transplantation warrants further evaluation.

Indexed as

Heart TransplantationKidney TransplantationLiver TransplantationAdaptor Proteins, Signal TransducingAdolescentBone and BonesBone Morphogenetic ProteinsChildCross-Sectional StudiesFemaleFibroblast Growth Factor-23Fibroblast Growth FactorsGenetic MarkersHumansMaleOsteocytesAdaptor Proteins, Signal TransducingBone Morphogenetic ProteinsFGF23 protein, humanFibroblast Growth Factor-23Fibroblast Growth FactorsGenetic MarkersSOST protein, human

Identifiers

PMID26390291
PMCPMC4577074
OpenAlexW2220778557

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.